Information Provided By:
Fly News Breaks for February 28, 2020
GILD, LGND
Feb 28, 2020 | 07:27 EDT
Benchmark analyst Robert Wasserman noted that Ligand (LGND) raised its financial guidance due to recent shipments of its Captisol cyclodextrin for use in clinical studies of Gilead's (GILD) antiviral drug remdesivir for the treatment of the new coronavirus, or COVID-19. Following the FDA's recent rapid review and acceptance of Gilead's IND filing for remdesivir for the treatment of COVID-19 the company has announced the initiation of two Phase 3 clinical studies for the drug to treat the new disease, noted Wasserman, who called partner Ligand a "coronavirus play in the making." He reiterates a Buy rating and $135 price target on Ligand shares.
News For LGND;GILD From the Last 2 Days
GILD
Oct 25, 2021 | 08:09 EDT
Aadi Bioscience (AADI) announced the appointment of Loretta Itri, M.D., FACP, to the role of Chief Medical Officer, CMO. Most recently, Dr. Itri was Chief Medical Officer at Immunomedics, where she oversaw the development program and approval of TRODELVY, the first TROP-2 directed antibody-drug conjugate for the treatment of unresectable locally advanced or metastatic triple-negative breast and urothelial cancers. Immunomedics was subsequently acquired by Gilead Sciences (GILD).